Shidi Wen^1,2,#, Lu Wang^1,2,#, Ying Jiang³, Zhiyang Zhang^4,*, Yuejuan Cheng^4,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.080462 - 16 July 2026

Abstract Background: Hidradenocarcinoma is a rare and highly aggressive malignancy with limited therapeutic options. This report describes the clinical course and treatment response of a patient with recurrent metastatic hidradenocarcinoma treated with sequential immunochemotherapy combined with anti-angiogenic therapy, with the aim of providing further insight into potential treatment strategies for this rare malignancy. Case Description: A 60-year-old male initially presented in 2020 with scrotal erythema and was diagnosed with hidradenocarcinoma after surgery. Despite surgical treatment, he developed recurrent disease with diffuse metastases. First-line chemoimmunotherapy (sintilimab, cisplatin, 5-fluorouracil; six cycles) achieved a progression-free survival (PFS) of 6 months. Following… More >

Zhihao Wei^1,#, Jijie Cai^1,#, Sifen Wang^2,#, Yachen Li³, Libo Luo¹, Jun Chen¹, Fuyu Li¹, Hongyu Nie¹, Ke Gong^4,*, Manbo Cai^1,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.079281 - 16 July 2026

Abstract Breast cancer (BC) remains a leading cause of cancer-related mortality worldwide, and accumulating evidence suggests that tumor-associated microbiota may contribute to disease heterogeneity beyond host genetic and immune determinants. Advances in sequencing and multi-omics technologies have uncovered a reproducible intratumoral microbiome in BC, with distinct compositional patterns associated with molecular subtypes, clinicopathological features, and clinical outcomes. Alterations in specific microbial taxa have also been linked to tumor immune status, metastatic potential, and therapeutic sensitivity, underscoring their potential value in disease stratification and prognostic assessment. Although breast tissue represents a low-biomass environment, multiple studies employing stringent… More >

Francesco Claps^1,2,*, Miguel Ramírez-Backhaus¹, Álvaro Gómez-Ferrer¹, Juan Manuel Mascarós¹, Argimiro Collado Serra¹, Augusto Wong¹, Ana Calatrava Fons³, Miguel Ángel Climent⁴, Antonio Amodeo², Angelo Porreca⁵, Jose Rubio-Briones^1,6

Canadian Journal of Urology, Vol.33, No.3, pp. 593-602, 2026, DOI:10.32604/cju.2025.070162 - 29 June 2026

Abstract Objectives: Residual Disease after adjuvant chemotherapy for non-seminomatous germ cell tumor (NSGCT) poses a significant clinical challenge and difficulties in tailored management. This study aimed to externally validate the Heidenreich criteria among patients eligible for unilateral post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for residual masses of NSGCT. Methods: For validation, these criteria were retrospectively applied in 23 patients undergoing PC-RPLND for residual masses of NSGCTs. In patients qualified for unilateral-modified PC-RPLND according to the Heidenreich criteria but treated with fully bilateral dissection, pathological reports were evaluated to identify teratoma or active cancer cells inside the… More >

Wei Jiang¹, You Zheng¹, Zhouhong Jing², Xiangling Yu¹, Huiying Fang^2,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.078278 - 21 May 2026

Abstract Background: Breast cancer treatment is often hampered by the immunosuppressive tumor microenvironment (TME). To improve therapeutic efficacy, this study developed a folic acid-chitosan (FA-CS)-modified liposomal formulation co-delivering doxorubicin (DOX) and resiquimod (R848) for combined chemotherapy and immune modulation. Methods: The FA-CS-R848/DOX@Lip liposomes were prepared by rotary evaporation and characterized for morphology, particle size, zeta potential, drug encapsulation efficiency (EE), drug loading (DL) capacity, and drug release profiles. Cellular uptake and cytotoxicity were determined to assess the biological effects of the formulation. Antitumor efficacy and biosafety were assessed in an EO771 tumor-bearing mouse model. The macrophage phenotype,… More >

Mariana Lopes^1,#, Carlos Vila Nova^2,3,#, Rui Caetano Oliveira^3,4, Fernando Schmitt⁵, Fernando Mendes^1,6,7,8,9,*, Diana Martins^1,6,7,8

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.074215 - 21 May 2026

Abstract Objectives: Triple-negative breast cancer (TNBC) accounts for approximately 15% of all invasive breast cancers and is characterized by aggressive behavior, limited therapeutic options, and poor clinical outcomes. Due to the absence of hormone receptors and HER2 expression, systemic treatment relies predominantly on chemotherapy, which is associated with high rates of early recurrence and mortality. Emerging evidence suggests that alterations in the microbiome can contribute to TNBC progression and influence therapeutic response, particularly affecting the efficacy of chemotherapy and immunotherapy through immune-mediated mechanisms; however, its role in TNBC remains incompletely understood. This systematic review aims to explore… More >

Carlo Ronsini^1,*, Giuseppe Cucinella¹, Maria Cristina Solazzo¹, Mariano Catello Di Donna¹, Cono Scaffa¹, Stefano Cianci², Manuela Ludovisi³, Sandro Pignata⁴, Vito Chiantera¹

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.074934 - 22 April 2026

Abstract Background: The optimal sequencing of surgery and chemotherapy in advanced epithelial ovarian cancer remains debated. While primary debulking surgery (PDS) has been considered the standard approach, recent randomized trials have questioned its survival advantage over neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). The study aimed to systematically evaluate phase III randomized controlled trials comparing PDS and NACT. Methods: Following PRISMA guidelines (PROSPERO ID 1169057), PubMed and Scopus were systematically searched in October 2025 for phase III randomized clinical trials evaluating cytoreductive strategies in ovarian carcinoma. Only full-text English studies reporting overall survival (OS)… More >

Xie Ding^1,2,3,#, Xinfeng Liu^4,#, Cheng Dai⁵, Xiaoxiao Wang^1,2,3, Zhaopeng Zheng^2,3,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.071213 - 22 April 2026

Abstract Background: Immunotherapy has markedly reshaped the therapeutic landscape for patients with postoperative progression and metastasis. As a programmed death-1 (PD-1) inhibitor, camrelizumab has been proven to exhibit both efficacy and safety in the treatment of advanced dMMR solid tumors. Case Description: A 58-year-old female patient with neuroendocrine carcinoma of the endometrium (NECE) who was treated with camrelizumab coupled with chemotherapy, subsequent maintenance monotherapy with camrelizumab, and adjuvant pelvic local radiotherapy. Up to December 2024, the patient has survived 28 months since treatment, with 26 months free from disease progression, and the assessment indicated a status of More >

Nadezhda Palkina¹, Aleksandra Esimbekova¹, Ekaterina Lapkina¹, Victoriia Kutsenko¹, Ivan Zinchenko¹, Egor Dereviankin¹, Elena Anisimova², Andrei Savchenko², Tatiana Ruksha^1,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.069234 - 22 April 2026

Abstract Background: Cancer cells are characterized by the ability to exit reversibly from the cell cycle to resist an unfavorable environment. This study elucidates alterations in adhesion molecule expression in melanoma cells acquiring resistance to dacarbazine (DTIC) and entering the G0 state. Plexin A2 (PLXNA2) was identified as a focal adhesion-related molecule implicated in carcinogenesis. Methods: Applying siRNA-mediated knockdown, the effects of altered PLXNA2 expression in melanoma cells were evaluated. PLXNA2 expression was determined by real-time quantitative reverse transcription PCR, immunoblotting, and immunocytochemistry. Cell cycle phase distribution among dacarbazine-treated cells and their apoptosis levels were quantified by… More >

Yin-Lun Chang^1,2, Hao-Lun Luo¹, Jei-Ming Peng^3,*, Chang-Chun Hsiao^2,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.070837 - 23 March 2026

Abstract Background: Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with high recurrence rates. Lymphovascular invasion (LVI) predicts a poor prognosis, yet its molecular drivers remain unclear. BOC cell adhesion-associated, oncogene-regulated (BOC, also known as Brother of CDO [Cell adhesion molecule-Related/Down-regulated by Oncogenes]), a hedgehog-related cell surface receptor, may serve as a biomarker for tumor progression and chemotherapy response. The study aimed to investigate the role of BOC in UTUC and its potential to predict LVI and chemotherapy response. Methods: Sequencing (RNA-seq) of 10 stage III UTUC, treatment-naïve, fresh tissue samples identified BOC as a… More >

Roberta Giorgione^1,#, Daniela Grasso^2,#, Elisabetta Gambale¹, Federico Scolari³, Virginia Rossi¹, Fabrizio Di Maida⁴, Marinella Micol Mela¹, Barbara Marzocchi², Laura Doni¹, Adriano Pasqui¹, Andrea Minervini⁴, Enrico Caliman¹, Sergio Serni^4,5,6, Andrea Bernini², Serena Pillozzi³, Lorenzo Antonuzzo^1,5,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.068896 - 23 March 2026

Abstract Objectives: To date, predictive and prognostic biomarkers for Bladder Cancer (BC) remain lacking. Existing literature underscores the potential of metabolomics as a valuable tool for biomarker identification. The primary objective of this study is to characterize the serum metabolic profile of BC patients undergoing platinum-based chemotherapy (Pt-CT) to identify potential biomarkers. Methods: In this pilot study, we investigated the metabolomic profiles of 14 BC patients undergoing Pt-CT in different settings. We compared their baseline profiles with those of healthy controls and tracked key metabolites throughout chemotherapy cycles. Metabolomics profiling was conducted using nuclear magnetic resonance… More >